Ireland· IE-PA-PA23355/013/006
Klacid 250 mg/5 ml Granules for Oral Suspension
A clarithromycin product containing clarithromycin, registered in Ireland by Viatris Healthcare Limited. The same ATC class is registered in 19 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Clarithromycin is registered in 19 of 19 countries.
Countries holding a registration under ATC J01FA09 (clarithromycin), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 11 of them publish a price we can compare per daily dose
Clarithromycin · ATC J01FA09
19 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of clarithromycin costs, country by country.
Normalised to the WHO defined daily dose (0.5 g), the median price runs from $0.65 in Italy to $2.90 in Switzerland — a ×4.5 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Clarithromycin · price per daily dose (0.5 g)
USD · FX 28 Sept 2026
- CH Switzerland$2.90
- FR France$0.94
- IT Italy$0.65
The record
At a glance
HPRA (Ireland)- Active substance
- Clarithromycin
- Manufacturer
- Viatris Healthcare Limited
- Country
- Ireland (IE)
- ATC code
- J01FA09
- ATC class
- Clarithromycin
- Defined daily dose
- 0.5 g, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberPA23355/013/006
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
1085 interactions on record for clarithromycin.
Graded by severity as the source publishes them — 274 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Clarithromycin · interactions on record
1085 records
- 274 severe
- 434 moderate
- 50 minor
- 256 info
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- NaloxegolA06AH03severe
71 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under J01FA09
Clarithromycin, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3db3340a-806b-4e9d-9f0b-fc949cb388b0 GET /v1/drugs/3db3340a-806b-4e9d-9f0b-fc949cb388b0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Granules for oral suspension",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"J01FA",
"J01FA09"
],
"strength": null,
"pa_number": "PA23355/013/006",
"substances": [
"Clarithromycin"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Marketed",
"authorised_at": "26/06/1998",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about clarithromycin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.